Healthcare provider profile · identity verified

Megan Bedeau, NP

Nurse Practitioner · NORFOLK, VA · NPI 1821621947

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	329	65
Amlodipine Besylate	Amlodipine Besylate	261	46
Metoprolol Succinate	Metoprolol Succinate	153	27
Gabapentin	Gabapentin	146	33
Losartan Potassium	Losartan Potassium	135	27
Lisinopril	Lisinopril	124	23
Levothyroxine Sodium	Levothyroxine Sodium	118	24
Pantoprazole Sodium	Pantoprazole Sodium	114	26
Furosemide	Furosemide	96	26
Omeprazole	Omeprazole	95	21
Quetiapine Fumarate	Quetiapine Fumarate	81	14
Clopidogrel	Clopidogrel Bisulfate	74	19
Allopurinol	Allopurinol	73	12
Donepezil Hcl	Donepezil Hcl	72	14
Eliquis	Apixaban	71	17
Latanoprost	Latanoprost	70	11
Rosuvastatin Calcium	Rosuvastatin Calcium	69	17
Trazodone Hcl	Trazodone Hcl	66	20
Pravastatin Sodium	Pravastatin Sodium	64	14
Sertraline Hcl	Sertraline Hcl	62	13
Carvedilol	Carvedilol	61	15
Memantine Hcl	Memantine Hcl	59	14
Hydralazine Hcl	Hydralazine Hcl	55	suppressed
Buspirone Hcl	Buspirone Hcl	54	11
Ozempic	Semaglutide	54	suppressed
Spironolactone	Spironolactone	49	11
Levetiracetam	Levetiracetam	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	46	27
Potassium Chloride	Potassium Chloride	46	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	45	12
Ezetimibe	Ezetimibe	44	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	44	11
Simvastatin	Simvastatin	43	suppressed
Famotidine	Famotidine	42	suppressed
Metformin Hcl Er	Metformin Hcl	42	suppressed
Montelukast Sodium	Montelukast Sodium	42	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	suppressed
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	40	11
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Pregabalin	Pregabalin	36	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	35	11
Duloxetine Hcl	Duloxetine Hcl	35	11
Metformin Hcl	Metformin Hcl	33	suppressed
Baclofen	Baclofen	32	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	31	suppressed
Alendronate Sodium	Alendronate Sodium	30	suppressed
Risperidone	Risperidone	29	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	28	21
Insulin Lispro Kwikpen U-100	Insulin Lispro	28	suppressed
Myrbetriq	Mirabegron	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Tramadol Hcl	Tramadol Hcl	26	12
Mirtazapine	Mirtazapine	25	suppressed
Olanzapine	Olanzapine	25	suppressed
Rybelsus	Semaglutide	25	suppressed
Bumetanide	Bumetanide	24	suppressed
Lacosamide	Lacosamide	23	suppressed
Valsartan	Valsartan	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Glipizide	Glipizide	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Trintellix	Vortioxetine Hydrobromide	21	suppressed
Trulicity	Dulaglutide	20	suppressed
Phenobarbital	Phenobarbital	19	suppressed
Primidone	Primidone	18	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	18	suppressed
Timolol Maleate	Timolol Maleate	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Torsemide	Torsemide	17	suppressed
Glipizide Er	Glipizide	16	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	16	suppressed
Verapamil Sr	Verapamil Hcl	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Insulin Aspart Prot Mix 70-30	Insulin Aspart Prot/Insuln Asp	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Cephalexin	Cephalexin	14	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	14	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Anastrozole	Anastrozole	13	suppressed
Buprenorphine	Buprenorphine	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Prednisone	Prednisone	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Auryxia	Ferric Citrate	12	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Metformin Er Osmotic	Metformin Hcl	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Mirabegron Er	Mirabegron	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Finasteride	Finasteride	11	suppressed
Gabapentin Er	Gabapentin	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error